Breaking News

Frontida Expands Testing Capabilities

Launches CAT.one testing to support abuse-deterrent product development.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Frontida BioPharm, a pharmaceutical contract development and manufacturing organization (CDMO) based in Philadelphia and Chicago areas, has launched its new Category 1 (CAT.ONE) in vitro testing and evaluation services to support development and regulatory approvals for abuse-deterrent formulations of pain management and Central Nervous System (CNS) targeted therapies.   To enable the launch of its CAT.ONE services, Frontida has hired a team of industry-recognized scientists with a proven track ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters